These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 6139281

  • 21. Dose-response relationship in normal subjects of prenalterol, a beta-adrenergic agonist with positive inotropic and resistance lowering effects.
    Rasmussen S, Høilund-Carlsen PF, Hesse B, Hartling OJ, Fabricius J, Dige-Petersen H, Giese J.
    Eur J Clin Pharmacol; 1984; 27(5):539-43. PubMed ID: 6151507
    [Abstract] [Full Text] [Related]

  • 22. Effect of prenalterol on contractility, relaxation, and filling phase in coronary artery disease patients with previous myocardial infarction.
    Cucchini F, Baldi G, Bolognesi R, Ferrari R, Visioli O.
    J Cardiovasc Pharmacol; 1984; 6(5):822-8. PubMed ID: 6209486
    [Abstract] [Full Text] [Related]

  • 23. The haemodynamic effects of dopamine and prenalterol in patients after cardiac valve surgery.
    Tydén H, Johansson L, Nyström SO.
    Acta Anaesthesiol Scand; 1982 Oct; 26(5):468-73. PubMed ID: 6128857
    [Abstract] [Full Text] [Related]

  • 24. Dose-dependent haemodynamic response to prenalterol in patients with congestive heart failure.
    Leinberger H, Mäurer W, Haueisen H, Schuler G, Kübler W.
    Acta Med Scand Suppl; 1982 Oct; 659():299-306. PubMed ID: 6127896
    [Abstract] [Full Text] [Related]

  • 25. The haemodynamic effects of intravenous prenalterol and ouabain in conscious dogs.
    Ek L, Björkman JA, Carlsson E, Johansson B.
    Acta Med Scand Suppl; 1982 Oct; 659():39-52. PubMed ID: 6127899
    [Abstract] [Full Text] [Related]

  • 26. Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol.
    Roubin GS, Choong CY, Devenish-Meares S, Sadick NN, Fletcher PJ, Kelly DT, Harris PJ.
    Circulation; 1984 May; 69(5):955-62. PubMed ID: 6142775
    [Abstract] [Full Text] [Related]

  • 27. Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.
    Currie PJ, Kelly MJ, Middlebrook K, Federman J, Sainsbury E, Ashley J, Pitt A.
    Br Heart J; 1984 May; 51(5):530-8. PubMed ID: 6326784
    [Abstract] [Full Text] [Related]

  • 28. Cardio-selective beta adrenergic stimulation with prenalterol in the conscious dog.
    Manders WT, Vatner SF, Braunwald E.
    J Pharmacol Exp Ther; 1980 Oct; 215(1):266-70. PubMed ID: 6109017
    [Abstract] [Full Text] [Related]

  • 29. Hemodynamic actions of prenalterol in severe congestive heart failure due to chronic coronary disease.
    Awan NA, Needham KE, Evenson MK, Win A, Mason DT.
    Am Heart J; 1981 Feb; 101(2):158-61. PubMed ID: 7468416
    [Abstract] [Full Text] [Related]

  • 30. Prenalterol, an oral beta-1 adrenoceptor agonist, in the treatment of chronic heart failure.
    Sharpe DN, Coxon R.
    Eur J Clin Pharmacol; 1983 Feb; 25(4):539-45. PubMed ID: 6653650
    [Abstract] [Full Text] [Related]

  • 31. Effects of prenalterol on cardiac performance and transmural myocardial perfusion in patients with chronic renal failure.
    Pedersen T, Cleemann-Rasmussen K, Brynjolf I, Ording H, Nielsen PE, Rasmussen K.
    Eur J Clin Pharmacol; 1983 Feb; 25(3):287-92. PubMed ID: 6628515
    [Abstract] [Full Text] [Related]

  • 32. Metabolic effects of prenalterol in diabetic patients.
    Oltmanns D.
    Acta Med Scand Suppl; 1982 Feb; 659():147-55. PubMed ID: 6127885
    [Abstract] [Full Text] [Related]

  • 33. Metabolic and haemodynamic effects and pharmacokinetics of a new selective beta 1-adrenoceptor agonist, prenalterol, in man.
    Rönn O, Fellenius E, Graffner C, Johnsson G, Lundborg P, Svensson L.
    Eur J Clin Pharmacol; 1980 Feb; 17(2):81-6. PubMed ID: 6102914
    [Abstract] [Full Text] [Related]

  • 34. Immediate haemodynamic effects of prenalterol, a new adrenergic beta-1-receptor agonist, in healthy volunteers.
    Svendsen TL, Hartling OJ, Trap-Jensen J.
    Eur J Clin Pharmacol; 1980 Oct; 18(3):219-23. PubMed ID: 6108219
    [Abstract] [Full Text] [Related]

  • 35. Changes in coronary haemodynamics and myocardial metabolism at rest and during exercise after a cardiotonic drug (prenalterol) in patients with coronary artery disease.
    Westheim A, Bae E, Christensen CC, Fønstelien E, Grendahl H, Muller O.
    Clin Physiol; 1988 Oct; 8(5):463-74. PubMed ID: 3191661
    [Abstract] [Full Text] [Related]

  • 36. Influence of heart rate on the effects of prenalterol on regional myocardial blood flow and function during coronary stenosis in dogs.
    Berdeaux A, Bonhenry C, Duhazé P, Giudicelli JF, Thuillez C.
    Br J Pharmacol; 1984 Sep; 83(1):203-10. PubMed ID: 6148979
    [Abstract] [Full Text] [Related]

  • 37. Acute effects of beta 1 agonism with prenalterol on catecholamine circulating levels in patients with congestive heart failure.
    Corea L, Bentivoglio M, Verdecchia P, Provvidenza M.
    G Ital Cardiol; 1983 Nov; 13(11):330-4. PubMed ID: 6141975
    [Abstract] [Full Text] [Related]

  • 38. Clinical results with prenalterol in patients with heart failure.
    Waagstein F, Reiz S, Ariniego R, Hjalmarson A.
    Am Heart J; 1981 Sep; 102(3 Pt 2):548-54. PubMed ID: 7270401
    [Abstract] [Full Text] [Related]

  • 39. The immediate haemodynamic and electrophysiological response to prenalterol during fixed rate pacing in patients with chronic ischaemic heart disease.
    Sire S, Amlie JP, Simonsen S.
    Acta Pharmacol Toxicol (Copenh); 1986 Jan; 58(1):43-8. PubMed ID: 3953293
    [Abstract] [Full Text] [Related]

  • 40. [Prenalterol (CGP 7760 B), a new cardioselective beta 1-adrenoceptor-agonist (author's transl)].
    Piepenbrock S, Reichelt W, Zenz M, Seitz W, Sikalieh E.
    Anaesthesist; 1981 Mar; 30(3):118-23. PubMed ID: 6111933
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.